Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome

Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome

IntroductionBlau syndrome is a rare autosomal dominant autoinflammatory granulomatous disease caused by a mutation in the NOD2 gene. It is characterized by a clinical trial of granulomatous dermatitis, arthritis, and uveitis. Tofacitinib is a pan Janus kinase (JAK) inhibitor used for treatment of Bl...

Full description

Bibliographic Details
Main Authors: Yoko Ueki, Riko Takimoto-Ito, Megumu K. Saito, Hideaki Tanizaki, Naotomo Kambe
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
autoinflammatory disease
Blau syndrome
NOD2
JAK-STAT signaling pathway
tofacitinib
IFNγ
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1211240/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1211240/full

Similar Items